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Jenuth JP, Peterson AC, Fu K, Shoubridge EA (1996) Random ranging from the ﬁrst muscle exon to the ﬁrst muscle
genetic drift in the female germline explains the rapid segre- intron, in the DMD gene in these patients (Yoshida et
gation of mammalian mitochondrial DNA. Nat Genet 14: al. 1993).
146–151 Meanwhile, the term ‘‘X-linked dilated cardiomyopa-
Johns DR (1996) The other human genome: mitochondrial thy’’ (‘‘XLDCM,’’ ‘‘XLCM,’’ or ‘‘XLDC’’), originally
DNA and disease. Nat Med 2:1065–1068
proposed by Berko and Swift (1987), now is assignedLander ES, Schork NJ (1994) Genetic dissection of complex
to a clinical phenotype of dystrophinopathy that is char-traits. Science 265:2037–2048
acterized by severe dilated cardiomyopathy without ap-Luft R (1994) The development of mitochondrial medicine.
parent skeletal myopathy (Muntoni et al. 1993; TowbinProc Natl Acad Sci USA 91:8731–8738
et al. 1993). To date, ﬁve mutations in the DMD geneSAS Institute (1987) SAS/STAT guide for personal computers,
version 6 ed. SAS Institute, Cary, NC have been reported in this phenotype (Muntoni et al.
Shigenaga MK, Hagen TM, Ames BN (1994) Oxidative dam- 1993; Oldfors et al. 1994; Towbin et al. 1994; Franz et
age and mitochondrial decay in aging. Proc Natl Acad Sci al. 1995; Milasin et al. 1996), and a correlation between
USA 91:10771–10778 the XLDCM phenotype and the locations of mutations
Suomalainen A, Kaukonen J, Amati P, Timonen R, Haltia M, in the DMD gene has been controversial. Among these
Weissenbach J, Zeviani M, et al (1995) An autosomal locus mutations, two were identiﬁed at the 5 end of the DMD
predisposing to deletions of mitochondrial DNA. Nat Genet
gene; one mutation was a deletion that removed the9:146–151
muscle promoter, the ﬁrst muscle exon, and part of theTorroni A, Schurr TG, Cabell MF, Brown MD, Neel JV,
ﬁrst muscle intron (Muntoni et al. 1993), and the otherLarsen M, Smith DG, et al (1993) Asian afﬁnities and conti-
was a point mutation in the 5 splice site of the ﬁrstnental radiation of the four founding Native American
muscle intron (Milasin et al. 1996). Together with ourmtDNAs. Am J Hum Genet 53:563–590
Wallace DC (1994) Mitochondrial DNA sequence variation report (Yoshida et al. 1993), these data indicate that the
in human evolution and disease. Proc Natl Acad Sci USA mutations at the 5 end of the DMD gene are associated
91:8739–8746 with a distinct phenotype of dystrophinopathy with
World Health Organization (WHO) (1985) Diabetes mellitus: preferential involvement of cardiac muscle. Further ex-
report of a WHO study group. Tech rep 727, WHO, Geneva aminations in XLDCM patients revealed that the expres-
sion of the brain and Purkinje-cell forms of dystrophin
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0002-9297/97/6006-0038$02.00 1996), suggesting that compensatory transcripts from
the brain and Purkinje-cell promoters may maintain ade-
quate levels of dystrophin in the skeletal muscle of
XLDCM patients (Muntoni et al. 1995; Milasin et al.
1996). We also analyzed the expression of each form
Am. J. Hum. Genet. 60:1555–1558, 1997 of dystrophin transcripts in one atypical BMD patient
(patient 1) with a deletion affecting the ﬁrst muscle exon
and the ﬁrst muscle intron, in the DMD gene, and alsoUp-Regulation of the Brain and Purkinje-Cell Forms
in two BMD patients, with typical skeletal muscleof Dystrophin Transcripts, in Becker Muscular
involvement, having a deletion of either exons 45–47Dystrophy
(patient 2) or exons 45–48 (patient 3).
To the Editor: Patient 1, a 24-year-old man, showed slight calf pseu-
dohypertrophy and exertional cramping myalgia in theDuchenne muscular dystrophy (DMD) and Becker mus-
cular dystrophy (BMD) are allelic disorders caused by legs but not muscle atrophy or weakness. He was free
of cardiac symptoms; however, an electrocardiogrammutations in the DMD gene. Clinical pictures in BMD
patients are more heterogeneous than those in DMD (ECG) showed an increased R/S ratio in leads V1 and
V2 and prominent Q waves in leads II, III, and aVF. Anpatients; some patients with BMD exhibit dilated car-
diomyopathy in the absence of overt skeletal muscle echocardiogram (UCG) revealed diffuse hypokinesis of
the left ventricle (LV), with dilatation (LV end–diastolicatrophy or weakness. We previously reported two atypi-
cal BMD patients from two unrelated families, who dimension [LVDd] of 64 mm, LV end–systolic dimen-
sion [LVDs] of 52 mm, and fractional shortening [FS]showed severe dilated cardiomyopathy in their teens
without obvious skeletal muscle atrophy or weakness of 19%). Especially the posterior wall of the LV was
markedly thin and akinetic. The LV ejection fraction(Yoshida et al. 1993). Both patients showed slight calf
pseudohypertrophy, and one of them had exertional my- (EF; normalú60%) was depressed severely (26%). Mild
mitral valve regurgitation also was observed. A 201Tlalgia. Molecular genetic analysis revealed a deletion
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Figure 1 Muscle-biopsy ﬁndings. All samples were obtained from the left-biceps brachii of the patients. A and D, Patient 1. B and E,
Patient 2 (E [inset], control). C and F, Patient 3. Panels A, B, and C show frozen sections stained with hematoxylin-eosin. Panels D, E, and F
show frozen sections stained with the antibody (dys 2) against the C-terminal domain of dystrophin. In patient 1 (D), all muscle ﬁbers showed
continuous dystrophin immunostaining, but the intensity of ﬂuorescence was paler than that in the control (E [inset]). Arrowheads indicate
opaque ﬁbers. The bars indicate 100 mm.
scintigram showed a decrease in uptake on the postero- Patient 2 was a 56-year-old man with atrophy and
weakness of proximal limb muscles, which started dur-lateral wall of the LV. His younger brother died at the
age of 18 years, because of congestive heart failure (Yo- ing his childhood. Since the age of 50 years, he occasion-
ally has experienced chest discomfort and nocturnalshida et al. 1993). Multiplex PCR and Southern blot
analysis conﬁrmed a unique deletion affecting part of the dyspnea. Cardiomegaly was noted on a chest roentgeno-
gram (cardiothoracic ratio of 55%). ECG showed aﬁrst muscle exon and intron in these siblings (Yoshida et
al. 1993). This deletion affected the initiation codon prominent Q wave in lead aVL, ST depression in leads
V1–V4, and negative T waves in leads V5 and V6. UCGATG in the ﬁrst muscle exon but not the muscle pro-
moter and the transcription start site. The genomic re- revealed LV hypokinesis with dilatation (LVDd of 59
mm, LVDs of 50 mm, and FS of 15%), decreased EF ofgions for the brain and Purkinje-cell promoters were
unaffected. The second exon also was intact. Hematoxy- 30%, and mild mitral valve regurgitation. Severe reduc-
tion of the 201Tl uptake was observed on the posteroinf-lin-eosin staining of the skeletal muscle of patient 1
showed that there was mild variation in ﬁber size, with erior wall and the apex of the LV. The muscle biopsy
revealed marked variation in ﬁber size, with rounda slight increase in the number of internal nuclei and
the presence of scattered opaque ﬁbers, although there atrophic ﬁbers, an increased number of internal nuclei,
and proliferation of connective tissue (ﬁg. 1B). The diag-were no necrotic ﬁbers and no increase of interstitial
connective tissue (ﬁg. 1A). Immunoﬂuorescence staining nosis of BMD was conﬁrmed by patchy and discontinu-
ous immunostaining of dystrophin in the biopsied mus-using antibodies against the N-terminal (dys 3 anti-
body), rod (dys 1 antibody), and C-terminal (dys 2 anti- cle (ﬁg. 1E) and by a deletion affecting exons 45–47 in
the DMD gene.body) domains (Novocastra Laboratories) showed that
all ﬁbers appeared to be labeled continuously but that Patient 3 was a 30-year-old man with muscle atrophy
and weakness in both thighs and with calf pseudohyper-the intensity of ﬂuorescence was weaker than that in
control skeletal muscle (ﬁg. 1D and E [inset]). In western trophy. He had right ankle joint contracture at birth and
could not walk until the age of 3 years. Since the age ofblot analysis using the dys 2 antibody, reduced amounts
of dystrophin were detected, but the size of the dys- 29 years, he has not been able to walk up stairs. A
physical examination at the age of 30 years showed thattrophin was normal (Ç400 kDa; data not shown).
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he had no cardiac symptoms or signs. ECG showed an
increased R/S ratio in lead V1 and abnormal Q waves
in leads I, aVL, and aVF. LV hypokinesis (LVDd of 52
mm, LVDs of 38 mm, and FS of 27%) and a slightly
decreased EF of 52% were detected by UCG. A 201Tl
scintigram revealed a mild reduction of uptake on the
posteroinferior and lateral walls of the LV. The histolog-
ical ﬁndings and the dystrophin immunostaining pat-
tern, of the skeletal muscles, were similar to those seen
in patient 2 (ﬁg. 1C and F). Patient 3 had a deletion
affecting exons 45–48 in the DMD gene.
We extracted total RNA from skeletal muscle speci-
mens from BMD patients and from a control patient
with dermatomyositis, using RNAzol (Tel-Test) in ac-
cordance with the manufacturer’s speciﬁcations. Re-
verse-transcription-PCR (RT-PCR) was performed with
the StratascriptTM RT-PCR kit. The forward oligonucle-
Figure 2 Expression pattern of dystrophin transcripts. RT-PCRotide primer (M1) used for ampliﬁcation of the muscle
ampliﬁcation of the muscle (lanes M), brain (lanes B), and Purkinje-form of dystrophin transcripts was the same in sequence
cell (lanes P) forms of dystrophin transcripts. The fragments with a
as that of primer 1F, which was described in the study size of 438 bp, 219 bp, and 240 bp correspond to the ampliﬁed muscle,
by Sakuraba et al. (1991). Forward primers for the brain brain, and Purkinje-cell forms, respectively, of dystrophin transcripts.
In the control, the muscle form was detected, but the brain and Pur-(B1) and Purkinje-cell (P1) forms of dystrophin tran-
kinje-cell forms were not detected. In contrast to the control, thescripts and the reverse primer (M4) located in exon 4
muscle form was undetectable in patient 1, whereas the brain andof the DMD gene were synthesized as described in the
Purkinje-cell forms were highly expressed. In the other two BMD
study by Muntoni et al. (1995). PCR was performed in patients (patients 2 and 3) with hot-spot deletions (of exons 45–47
a reaction volume of 50 ml, containing 1 mg of cDNA, and of exons 45–48, respectively), the brain and Purkinje-cell forms,
as well as the muscle form, were detected. The PCR products were100 ng of each primer, 0.5 mM of each dNTP, and
separated on 2.5% agarose gels and were stained with ethidium2.5 units of Taq DNA polymerase (Pharmacia Biotech).
bromide.Ampliﬁcation conditions were as follows: an initial de-
naturation at 94C for 5 min, followed by 35 cycles of
denaturation at 94C for 30 s; annealing at 62C for 1
min; and extension at 72C for 2 min, followed by a scripts in the skeletal muscle itself is not unique to the
XLDCM phenotype. We also speculate that the stabilityﬁnal extension for 10 min. In the control, the muscle
form, but not the brain and Purkinje-cell forms, of dys- and function of the brain and Purkinje-cell isoforms
should be critical to maintenance of the cytoskeletal or-trophin transcripts was detected. In contrast to the con-
trol, the muscle form was undetectable in patient 1, ganization of the skeletal muscle and to protection from
progressive degeneration of the muscles. In the case ofwhereas the brain and Purkinje-cell forms were highly
expressed (ﬁg. 2). The brain and Purkinje-cell forms so-called hot-spot mutations, such as those in patients
2 and 3, the brain and Purkinje-cell isoforms would bewere coexpressed with the muscle form, in the other two
BMD patients (patients 2 and 3; ﬁg. 2). The level of up- as unstable and ineffective as the muscle isoform, be-
cause they differ only in the N-terminal portion encodedregulation of the brain and Purkinje-cell forms was
much higher in patient 1 as compared with that in pa- by the isoform-speciﬁc ﬁrst exon.
We also found that the expression pattern of dystrophintients 2 and 3.
We ﬁrst conﬁrmed that the transcription of the brain transcripts in patient 1 was comparable to that of the
XLDCM patients reported by Muntoni et al. (1995) andand Purkinje-cell forms was signiﬁcantly up-regulated
in BMD patients with typical skeletal muscle involve- by Milasin et al. (1996). This strongly suggests that an
inactivation of the muscle promoter, in combination withment. It is likely that the promoters of the other forms,
as well as the muscle promoter, are activated compensa- an activation of the brain and Purkinje-cell promoters, is
characteristic to dystrophinopathy with selective cardiactively in these patients. These promoters probably re-
spond to reduced expression of dystrophin, but the ex- involvement caused by mutations in the 5 end of the
DMD gene. The transcription driven by the muscle pro-tent of activation of the brain and Purkinje-cell
promoters may vary between different patients; the pa- motermay be damaged selectively by this type ofmutation,
whereas it cannot be disturbed by hot-spot mutations, astients may differ in age, duration of disease, and degree
of daily activity. Our data suggest that up-regulation of seen in patients 2 and 3. To further elucidate the molecular
biological basis of the XLDCM phenotype, it will be ofthe brain and Purkinje-cell forms of dystrophin tran-
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in the 5 splice site of the dystrophin gene ﬁrst intron respon-much interest to examine the expression pattern of dys-
sible for X-linked dilated cardiomyopathy. Hum Mol Genettrophin transcripts in XLDCM patients with mutations
5:73–79outside the 5 end of the DMD gene, such as in the patients
Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddureported by Oldfors et al. (1994) (a deletion affecting ex-
A, Marrosu MG, et al (1993) Deletion of the dystrophinons 6–13), by Towbin et al. (1994) (a mutation within
muscle-promoter region associated with X-linked dilated
exons 8–10), and by Franz et al. (1995) (a mutation cardiomyopathy. N Engl J Med 329:921–925
around exons 27–30). Muntoni F, Melis MA, Ganau A, Dubowitz V (1995) Tran-
Our results, together with the report by Muntoni et scription of the dystrophin gene in normal tissues and in
al. (1995), also indicate that the sequence around the 5 skeletal muscle of a family with X-linked dilated cardiomy-
end of the ﬁrst muscle intron may be essential for the opathy. Am J Hum Genet 56:151–157
Oldfors A, Eriksson BO, Kyllerman M, Martinsson T, Wahl-functions of the muscle promoter, because this region
stro¨m J (1994) Dilated cardiomyopathy and the dystrophinconsistently is involved in these patients. In fact, Klamut
gene: an illustrated review. Br Heart J 72:344–348et al. (1996) recently have identiﬁed a transcriptional
Sakuraba H, Ishii K, Shimmoto M, Yamada H, Suzuki Yenhancer within the ﬁrst muscle intron of the human
(1991) A screening for dystrophin gene deletions in JapaneseDMD gene. Further molecular and cellular biological
patients with Duchenne/Becker muscular dystrophy by thestudies on dystrophinopathy with the XLDCM pheno-
multiplex polymerase chain reaction. Brain Dev 13:339–
type will help us understand the functions of dystrophin 342
promoters in the skeletal and cardiac muscles. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Cham-
In summary, we showed up-regulation of the brain berlain JS, McCabe ERB, et al. (1993) X-linked dilated car-
and Purkinje-cell forms of dystrophin transcripts not diomyopathy: molecular genetic evidence of linkage to the
only in an atypical BMD patient (patient 1) with the Duchenne muscular dystrophy (dystrophin) gene at the
Xp21 locus. Circulation 87:1854–1865XLDCM phenotype, but also in typical BMD patients
Towbin JA, Ortiz-Lopez R, Bulman D, Ray PN, Franz(patients 2 and 3). We think that the other isoforms of
W-M, Katus H, Swift M, et al. (1994) A novel cardio-speciﬁcdystrophin can modulate the clinical features and the
dystrophin mutation as a cause of X-linked dilated cardio-course of dystrophinopathy, especially with regard to
myopathy (XLCM). Pediatr Res Suppl 37:36Athe XLDCM phenotype.
Yoshida K, Ikeda S, Nakamura A, Kagoshima M, Takeda S,
Shoji S, Yanagisawa N (1993) Molecular analysis of theAKINORI NAKAMURA,1 SHU-ICHI IKEDA,1
Duchenne muscular dystrophy gene in patients with BeckerMASAHIDE YAZAKI,1 KUNIHIRO YOSHIDA,1
muscular dystrophy presenting with dilated cardiomyopa-OSAMU KOBAYASHI,2 NOBUO YANAGISAWA,1
thy. Muscle Nerve 16:1161–1166AND SHIN’ICHI TAKEDA2
1Department of Medicine (Neurology), Shinshu
Address for correspondence and reprints: Dr. Kunihiro Yoshida, DepartmentUniversity School of Medicine, Matsumoto; and of Medicine (Neurology), Shinshu University School of Medicine, 3-1-1 Asahi,
2National Institute of Neuroscience, National Center Matsumoto 390, Japan. E-mail: naokosy@gipac.shinshu-u.ac.jp
 1997 by The American Society of Human Genetics. All rights reserved.of Neurology and Psychiatry, Tokyo
0002-9297/97/6006-0039$02.00
Acknowledgments
This work was supported by the Research Grant for Ner-
vous and Mental Disorders (8A-2) from the Ministry of Health Am. J. Hum. Genet. 60:1558–1562, 1997
and Welfare, Japan.
Bilateral Retinoblastoma in a Male Patient with an
X;13 Translocation: Evidence for Silencing of the RB1References
Gene by the Spreading of X Inactivation
Berko BA, Swift M (1987) X-linked dilated cardiomyopathy.
To the Editor:N Engl J Med 316:1186–1191
Franz WM, Cremer M, Herrmann R, Gru¨nig E, Fogel W, We describe a male patient who has an X;13 transloca-
Scheffold T, Goebel HH, et al. (1995) X-linked dilated car- tion and bilateral retinoblastoma. DNA replication and
diomyopathy: novel mutation of the dystrophin gene. Ann methylation studies for this patient suggested that X
N Y Acad Sci 752:470–491
inactivation had spread to chromosome 13 and had pro-Klamut HJ, Bosnoyan-Collins LO, Worton RG, Ray PN, Davis
duced functional monosomy for genes on proximal 13q.HL (1996) Identiﬁcation of a transcriptional enhancer
Inactivation of both alleles of the RB1 gene in 13q14within muscle intron 1 of the human dystrophin gene. Hum
comprises the two rate-limiting steps in the formationMol Genet 5:1599–1606
of retinoblastoma (Knudson 1975; Cavenee et al. 1983).Milasin J, Muntoni F, Severini GM, Bartoloni L, Vatta M,
Krajinovic M, Mateddu A, et al (1996) A point mutation In hereditary retinoblastoma, one allele is inactivated or
/ 9a2a$$ju16 05-23-97 18:35:01 ajhga UC-AJHG
